Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening complication caused by platelet activation via platelet factor 4 (PF4) antibodies. We report a healthy 28-year-old man who developed hemoptysis, bilateral leg pain, and headaches three weeks after his third dose of the C...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/6/1115 |
| _version_ | 1797592474994081792 |
|---|---|
| author | Tzu-Chien Lin Pei-An Fu Ya-Ting Hsu Tsai-Yun Chen |
| author_facet | Tzu-Chien Lin Pei-An Fu Ya-Ting Hsu Tsai-Yun Chen |
| author_sort | Tzu-Chien Lin |
| collection | DOAJ |
| description | Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening complication caused by platelet activation via platelet factor 4 (PF4) antibodies. We report a healthy 28-year-old man who developed hemoptysis, bilateral leg pain, and headaches three weeks after his third dose of the COVID-19 vaccine with the first BNT162b2 (from Pfizer-BioNTech) injection. He had previously had the first and second doses with ChAdOx1 nCov-19 without any discomfort. Serial investigations demonstrated pulmonary embolisms, cerebral sinus, and deep iliac venous thrombosis. Positive PF4 antibody assay (ELISA) confirmed the diagnosis of VITT. He had a prompt response to intravenous immunoglobulins (IVIGs) at a total dose of 2 g/kg and his symptoms are now in remission with anticoagulant. Although the definite mechanism is unknown, the VITT was most likely triggered by his COVID-19 vaccine. We report this case of VITT following BNT162b2, a mRNA-based vaccine, and suggest that VITT could still happen without the adenoviral vector vaccines. |
| first_indexed | 2024-03-11T01:51:36Z |
| format | Article |
| id | doaj.art-f345cb8c097c49588e4c8631a27aeb4e |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T01:51:36Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-f345cb8c097c49588e4c8631a27aeb4e2023-11-18T12:59:26ZengMDPI AGVaccines2076-393X2023-06-01116111510.3390/vaccines11061115Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case ReportTzu-Chien Lin0Pei-An Fu1Ya-Ting Hsu2Tsai-Yun Chen3Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanDivision of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanDivision of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanVaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening complication caused by platelet activation via platelet factor 4 (PF4) antibodies. We report a healthy 28-year-old man who developed hemoptysis, bilateral leg pain, and headaches three weeks after his third dose of the COVID-19 vaccine with the first BNT162b2 (from Pfizer-BioNTech) injection. He had previously had the first and second doses with ChAdOx1 nCov-19 without any discomfort. Serial investigations demonstrated pulmonary embolisms, cerebral sinus, and deep iliac venous thrombosis. Positive PF4 antibody assay (ELISA) confirmed the diagnosis of VITT. He had a prompt response to intravenous immunoglobulins (IVIGs) at a total dose of 2 g/kg and his symptoms are now in remission with anticoagulant. Although the definite mechanism is unknown, the VITT was most likely triggered by his COVID-19 vaccine. We report this case of VITT following BNT162b2, a mRNA-based vaccine, and suggest that VITT could still happen without the adenoviral vector vaccines.https://www.mdpi.com/2076-393X/11/6/1115vaccine-induced immune thrombotic thrombocytopeniamRNA vaccineBNT162b2COVID-19 vaccine booster |
| spellingShingle | Tzu-Chien Lin Pei-An Fu Ya-Ting Hsu Tsai-Yun Chen Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report Vaccines vaccine-induced immune thrombotic thrombocytopenia mRNA vaccine BNT162b2 COVID-19 vaccine booster |
| title | Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report |
| title_full | Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report |
| title_fullStr | Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report |
| title_full_unstemmed | Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report |
| title_short | Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report |
| title_sort | vaccine induced immune thrombotic thrombocytopenia following bnt162b2 mrna covid 19 booster a case report |
| topic | vaccine-induced immune thrombotic thrombocytopenia mRNA vaccine BNT162b2 COVID-19 vaccine booster |
| url | https://www.mdpi.com/2076-393X/11/6/1115 |
| work_keys_str_mv | AT tzuchienlin vaccineinducedimmunethromboticthrombocytopeniafollowingbnt162b2mrnacovid19boosteracasereport AT peianfu vaccineinducedimmunethromboticthrombocytopeniafollowingbnt162b2mrnacovid19boosteracasereport AT yatinghsu vaccineinducedimmunethromboticthrombocytopeniafollowingbnt162b2mrnacovid19boosteracasereport AT tsaiyunchen vaccineinducedimmunethromboticthrombocytopeniafollowingbnt162b2mrnacovid19boosteracasereport |